Adjuvant treatment of early male breast cancer
- 25 August 2020
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Oncology
- Vol. 32 (6), 594-602
- https://doi.org/10.1097/cco.0000000000000678
Abstract
Purpose of review Male breast cancer (MaBC) is a rare disease, and some challenges exist in its management because current treatment recommendations are extrapolated from trials that mostly excluded men. This review will revise all available data that could improve the treatment of MaBC, with a special focus on adjuvant systemic treatments. Recent findings To date, men with hormone receptor-positive breast cancer, who are candidates for adjuvant endocrine therapy, should be offered tamoxifen (TAM) for five years. Additional five years are possible, according to tolerance and recurrence risk. If TAM is contraindicated, a gonadotropin-releasing hormone (GnRH) agonist or antagonist and aromatase inhibitor should be proposed. Chemotherapy and targeted therapy in the other breast cancer subtypes should be used with the same indications offered to women with breast cancer. All men with breast cancer should be offered genetic counseling and germline genetic testing of cancer predisposition genes. Summary For decades, men with breast cancer have been treated suboptimally and denied the participation in clinical trials. Recently, many clinical trials started enrolling both genders, as strongly endorsed by the Food and Drug Administration. Hopefully, this turnaround will help subdue the disparities in the quality of care.Keywords
This publication has 83 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Mutations in BRCA2 and PALB2 in male breast cancer cases from the United StatesBreast Cancer Research and Treatment, 2010
- Breast cancer in men in the United StatesCancer, 2010
- Adjuvant systemic therapy for male breast carcinomaCancer, 2005
- Breast carcinoma in menCancer, 2004
- Racial/ethnic differences in survival rates in a population‐based series of men with breast carcinoma†Cancer, 2002
- Male breast cancer: a 22-year experienceEuropean Journal of Surgical Oncology, 1998
- A review of the management of the male breast carcinoma based on an analysis of 420 treated casesThe Breast, 1996
- Male breast cancer: Results of the treatments and prognostic factors in 397 casesEuropean Journal of Cancer, 1995
- Review article: Epidemiology of male breast cancer. A meta‐analysis of published case‐control studies and discussion of selected aetiological factorsInternational Journal of Cancer, 1993